JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

Search

Akebia Therapeutics Inc

Open

BrancheGesundheitswesen

2.99 1.01

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.93

Max

3.03

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.9M

247K

Verkäufe

5.1M

62M

Gewinnspanne

0.395

Angestellte

181

EBITDA

-6.1M

7.4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+124.36% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-50M

838M

Vorheriger Eröffnungskurs

1.98

Vorheriger Schlusskurs

2.99

Nachrichtenstimmung

By Acuity

64%

36%

328 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Akebia Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Okt. 2025, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22. Okt. 2025, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22. Okt. 2025, 21:20 UTC

Ergebnisse

Correction to IBM 3Q Sales Jump Article

22. Okt. 2025, 20:57 UTC

Ergebnisse

SAP Posts Higher 3Q Revenue, Operating Profit

22. Okt. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Okt. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22. Okt. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:15 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22. Okt. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22. Okt. 2025, 22:02 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22. Okt. 2025, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22. Okt. 2025, 21:58 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22. Okt. 2025, 21:57 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22. Okt. 2025, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22. Okt. 2025, 21:47 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22. Okt. 2025, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22. Okt. 2025, 21:28 UTC

Market Talk
Ergebnisse

Correction to Alcoa Tariff Market Talk

22. Okt. 2025, 21:25 UTC

Ergebnisse

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22. Okt. 2025, 21:17 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22. Okt. 2025, 21:09 UTC

Market Talk
Ergebnisse

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22. Okt. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22. Okt. 2025, 20:59 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 20:51 UTC

Ergebnisse

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Okt. 2025, 20:44 UTC

Ergebnisse

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer-Vergleich

Kursveränderung

Akebia Therapeutics Inc Prognose

Kursziel

By TipRanks

124.36% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD  124.36%

Hoch 8 USD

Tief 6 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Akebia Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

2.345 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

328 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat